MétaCan
Menu
Back to cohort
Record W4210689349 · doi:10.1001/jamaoncol.2021.6744

Pathology of Tumors Associated With Pathogenic Germline Variants in 9 Breast Cancer Susceptibility Genes

2022· article· en· W4210689349 on OpenAlexafffund
Nasim Mavaddat, Leila Dorling, Sara Carvalho, Jamie Allen, Anna González‐Neira, Renske Keeman, Manjeet K. Bolla, Joe Dennis, Qin Wang, Thomas U. Ahearn, Irene L. Andrulis, Matthias W. Beckmann, Sabine Behrens, Javier Benı́tez, Marina Bermisheva, Carl Blomqvist, Natalia Bogdanova, Stig E. Bojesen, Ignacio Briceño, Thomas Brüning, Nicola J. Camp, Archie Campbell, Jose E. Castelao, Jenny Chang‐Claude, Stephen J. Chanock, Georgia Chenevix‐Trench, Hans Christiansen, Kamila Czene, Thilo Dörk, Mikael Eriksson, D. Gareth Evans, Peter A. Fasching, Jonine D. Figueroa, Henrik Flyger, Marike Gabrielson, Manuela Gago-Domínguez, Jürgen Geisler, Graham G. Giles, Pascal Guénel, Andreas Hadjisavvas, Eric Hahnen, Per Hall, Ute Hamann, Jaana M. Hartikainen, Mikael Hartman, Reiner Hoppe, Anna Jakubowska, Audrey Jung, Э. К. Хуснутдинова, Vessela N. Kristensen, Jingmei Li, Swee Ho Lim, Annika Lindblom, Maria A. Loizidou, Artitaya Lophatananon, Jan Lubiński, Michael J. Madsen, Mehdi Manoochehri, Sara Margolin, Dimitrios Mavroudis, Roger L. Milne, Nur Aishah Mohd Taib, Anna Morra, Kenneth Muir, Nadia Obi, Ana Osório, Tjoung‐Won Park‐Simon, Paolo Peterlongo, Paolo Radice, Emmanouil Saloustros, Elinor J. Sawyer, Rita K. Schmutzler, Mitul Shah, Xueling Sim, Melissa C. Southey, Heather Thorne, Ian Tomlinson, Diana Torres, Thérèse Truong, Cheng Har Yip, Amanda B. Spurdle, Maaike P.G. Vreeswijk, Alison M. Dunning, Montserrat García‐Closas, Paul D.P. Pharoah, Anders Kvist, Taru Muranen, Heli Nevanlinna, Soo‐Hwang Teo, Peter Devilee, Marjanka K. Schmidt, Douglas F. Easton

Bibliographic record

VenueJAMA Oncology · 2022
Typearticle
Languageen
FieldBiochemistry, Genetics and Molecular Biology
TopicBRCA gene mutations in cancer
Canadian institutionsLunenfeld-Tanenbaum Research InstituteUniversity of TorontoMount Sinai Hospital
FundersMedical Research and Materiel CommandDavid Geffen School of Medicine, University of California, Los AngelesEuropean Regional Development FundNational Cancer InstituteMedisinske fakultet, Universitetet i OsloServicio Gallego de SaludUniversitätsklinikum Hamburg-EppendorfScottish GovernmentKWF KankerbestrijdingDet Sundhedsvidenskabelige Fakultet, Københavns UniversitetInstituto de Salud Carlos IIIFreistaat SachsenRussian Academy of SciencesMedical Research CouncilEuropean CommissionCanadian Institutes of Health ResearchDirectorate for Biological SciencesNational Institutes of HealthUniversité de Versailles Saint-Quentin-en-YvelinesUniversitätsklinikum KölnAkershus UniversitetssykehusNational University Health SystemAgency for Science, Technology and ResearchUniversidad de La SabanaPomorski Uniwersytet Medyczny W SzczecinieInstitut Gustave-RoussyUniversität zu KölnFondazione Italiana per la Ricerca sul CancroMedizinischen Hochschule HannoverKreftforeningenInstitut National Du CancerLeids Universitair Medisch CentrumKarolinska InstitutetAssociazione Italiana per la Ricerca sul CancroDeutsche KrebshilfeNational Health and Medical Research CouncilUniversiti MalayaNorges ForskningsrådNational Medical Research CouncilStockholms Läns LandstingSundhed og Sygdom, Det Frie ForskningsrådSaint Petersburg State UniversityKuopion Yliopistollinen SairaalaUniversity of TorontoPontificia Universidad JaverianaKing's College LondonGentofte HospitalDeutsche ForschungsgemeinschaftDeutsche Gesetzliche UnfallversicherungAlexander von Humboldt-StiftungCancerfondenCancer Council VictoriaUniversity of MelbourneRobert Bosch StiftungProgramme Grants for Applied ResearchManchester Biomedical Research CentreMonash UniversityItä-Suomen YliopistoEberhard Karls Universität TübingenUniversiteit LeidenCancer Research InstituteUniversity of CreteInstitut National de la Santé et de la Recherche MédicaleInstitute of GeneticsWellcome TrustAgence Nationale de la RechercheLunds UniversitetFaculty of Health and Medical Sciences, University of Western AustraliaCancer Research UKNational University of SingaporeNational Research Foundation SingaporeNational Institute for Health and Care ResearchNIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer ResearchNational Research FoundationChief Scientist Office, Scottish Government Health and Social Care DirectorateBundesministerium für Bildung und ForschungGenome Institute of SingaporeNational Breast Cancer FoundationQIMR Berghofer Medical Research InstituteResearch Promotion FoundationEngineering and Physical Sciences Research CouncilFondation de FranceUniversity of CambridgeGovernment of CanadaBreast Cancer Research TrustFondation du cancer du sein du QuébecDuke-NUS Medical SchoolHuntsman Cancer InstituteScottish Funding CouncilInstituto de Investigación Sanitaria de Santiago de CompostelaDeutsches KrebsforschungszentrumHelsingin YliopistoGenome CanadaUniversity of California, San DiegoUniversitetet i OsloUniversity of OxfordCancer Council NSWSusan G. Komen for the Cure
KeywordsMedicineGermlineBreast cancerGeneGermline mutationCancerPathologyOncologyGeneticsInternal medicineMutationBiology

Abstract

fetched live from OpenAlex

IMPORTANCE: Rare germline genetic variants in several genes are associated with increased breast cancer (BC) risk, but their precise contributions to different disease subtypes are unclear. This information is relevant to guidelines for gene panel testing and risk prediction. OBJECTIVE: To characterize tumors associated with BC susceptibility genes in large-scale population- or hospital-based studies. DESIGN, SETTING, AND PARTICIPANTS: The multicenter, international case-control analysis of the BRIDGES study included 42 680 patients and 46 387 control participants, comprising women aged 18 to 79 years who were sampled independently of family history from 38 studies. Studies were conducted between 1991 and 2016. Sequencing and analysis took place between 2016 and 2021. EXPOSURES: Protein-truncating variants and likely pathogenic missense variants in ATM, BARD1, BRCA1, BRCA2, CHEK2, PALB2, RAD51C, RAD51D, and TP53. MAIN OUTCOMES AND MEASURES: The intrinsic-like BC subtypes as defined by estrogen receptor, progesterone receptor, and ERBB2 (formerly known as HER2) status, and tumor grade; morphology; size; stage; lymph node involvement; subtype-specific odds ratios (ORs) for carrying protein-truncating variants and pathogenic missense variants in the 9 BC susceptibility genes. RESULTS: The mean (SD) ages at interview (control participants) and diagnosis (cases) were 55.1 (11.9) and 55.8 (10.6) years, respectively; all participants were of European or East Asian ethnicity. There was substantial heterogeneity in the distribution of intrinsic subtypes by gene. RAD51C, RAD51D, and BARD1 variants were associated mainly with triple-negative disease (OR, 6.19 [95% CI, 3.17-12.12]; OR, 6.19 [95% CI, 2.99-12.79]; and OR, 10.05 [95% CI, 5.27-19.19], respectively). CHEK2 variants were associated with all subtypes (with ORs ranging from 2.21-3.17) except for triple-negative disease. For ATM variants, the association was strongest for the hormone receptor (HR)+ERBB2- high-grade subtype (OR, 4.99; 95% CI, 3.68-6.76). BRCA1 was associated with increased risk of all subtypes, but the ORs varied widely, being highest for triple-negative disease (OR, 55.32; 95% CI, 40.51-75.55). BRCA2 and PALB2 variants were also associated with triple-negative disease. TP53 variants were most strongly associated with HR+ERBB2+ and HR-ERBB2+ subtypes. Tumors occurring in pathogenic variant carriers were of higher grade. For most genes and subtypes, a decline in ORs was observed with increasing age. Together, the 9 genes were associated with 27.3% of all triple-negative tumors in women 40 years or younger. CONCLUSIONS AND RELEVANCE: The results of this case-control study suggest that variants in the 9 BC risk genes differ substantially in their associated pathology but are generally associated with triple-negative and/or high-grade disease. Knowing the age and tumor subtype distributions associated with individual BC genes can potentially aid guidelines for gene panel testing, risk prediction, and variant classification and guide targeted screening strategies.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.002
Threshold uncertainty score0.006

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.001
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0020.001
Science and technology studies0.0000.000
Scholarly communication0.0010.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0020.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.011
GPT teacher head0.281
Teacher spread0.270 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations190
Published2022
Admission routes2
Has abstractyes

Explore more

Same venueJAMA OncologySame topicBRCA gene mutations in cancerFrench-language works237,207